Biphenyl Compounds

• 

  Subject Areas on Research

  • 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding. 
  • 4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors. 
  • A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method. 
  • A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. 
  • ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. 
  • Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. 
  • Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. 
  • Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. 
  • Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 
  • Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. 
  • Albuminuria in chronic heart failure: prevalence and prognostic importance. 
  • An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1. 
  • Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. 
  • Angioedema induced by the angiotensin II blocker losartan. 
  • Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. 
  • Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin. 
  • Angiotensin II promotes development of the renal microcirculation through AT1 receptors. 
  • Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. 
  • Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. 
  • Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. 
  • Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 
  • Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 
  • Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. 
  • Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Comparative toxicity of polychlorinated biphenyl and polybrominated biphenyl in the rat liver: light and electron microscopic alterations after subacute dietary exposure. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. 
  • Copper complexes containing thiosemicarbazones derived from 6-nitropiperonal: Antimicrobial and biophysical properties. 
  • Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. 
  • Current-use flame retardants: Maternal exposure and neurodevelopment in children of the CHAMACOS cohort. 
  • DIRECT new treatments for diabetic retinopathy. 
  • Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. 
  • Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. 
  • Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. 
  • Demographic and dietary risk factors in relation to urinary metabolites of organophosphate flame retardants in toddlers. 
  • Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 
  • Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. 
  • Diphenyl Phosphate-Induced Toxicity During Embryonic Development. 
  • Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. 
  • Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice. 
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
  • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. 
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. 
  • Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. 
  • Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. 
  • Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. 
  • Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process. 
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. 
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 
  • Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. 
  • Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. 
  • Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. 
  • Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. 
  • Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. 
  • Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment? 
  • Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. 
  • Losartan in post-transplant erythrocytosis. 
  • MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration. 
  • Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure. 
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. 
  • Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. 
  • NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. 
  • New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. 
  • Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. 
  • Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. 
  • Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. 
  • Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. 
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. 
  • Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. 
  • Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. 
  • Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Reclassifying heart failure: time for disruptive innovation? 
  • Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. 
  • Renal segmental microvascular responses to ANG II in AT1A receptor null mice. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Role of cholinergic mechanisms in states of wakefulness and sleep. 
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full? 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. 
  • Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? 
  • Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. 
  • Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. 
  • Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. 
  • Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma. 
  • Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. 
  • The CHARM programme. 
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. 
  • The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? 
  • The association of urinary phosphorous-containing flame retardant metabolites and self-reported personal care and household product use among couples seeking fertility treatment. 
  • The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. 
  • The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. 
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. 
  • Thromboxane binding and signal transduction in rat glomerular mesangial cells. 
  • Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats. 
  • Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. 
  • Towards establishing indicative values for metabolites of organophosphate ester contaminants in human urine. 
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.